In people with painful diabetic peripheral neuropathy (DPN), changes in how the brain processes pain have been observed. However, until now, researchers hadn’t looked at how stopping pain treatment might affect brain activity in these individuals.

      A recent study, published in Diabetes in August 2024, explored this by scanning the brains of 16 participants who were being treated for neuropathic pain. These scans were done twice: once while they were on their pain medication and again one week after they stopped their treatment.

      The results showed an increase in brain activity between key pain-processing areas—the thalamus, primary somatosensory cortex (S1), and the insular cortex—after treatment was stopped. The more severe the pain participants felt at the start of the study, the greater the change in brain activity after treatment withdrawal.

      Interestingly, people with higher levels of pain showed much greater changes in brain connectivity than those with lower pain levels. This suggests that brain scans could potentially serve as an objective measure of pain in people with DPN.

      In conclusion, this study shows that brain activity may act as a biomarker for tracking pain levels in diabetes-related neuropathy and could be used to monitor the effectiveness of treatments in future clinical trials.